Impact of L-type amino acid transporter 3 on the prognosis of hepatocellular carcinoma.
HCC
LAT3
amino acid
leucine
p-AKT
Journal
Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
21
06
2022
accepted:
06
09
2022
entrez:
17
10
2022
pubmed:
18
10
2022
medline:
18
10
2022
Statut:
epublish
Résumé
The aim of the present study was to investigate the impact of L-type amino acid transporter 3 (LAT3) expression on the prognosis of hepatocellular carcinoma (HCC). A total of 135 patients who had undergone initial hepatic resection for HCC at Tokushima University Hospital (Tokushima, Japan) were enrolled in the present study. Immunohistochemical analysis of LAT3 and phosphorylated AKT (p-AKT) was performed using resected specimens. Clinicopathological factors, including prognosis, were compared between the LAT3-high and -low expression groups. The results demonstrated that the LAT3-high group showed significantly higher protein induced by vitamin K absence-II levels (P=0.01) compared with the LAT3-low group. The LAT3-high group showed significantly worse prognosis compared with the LAT3-low group regarding cancer-specific survival and disease-free survival (P<0.05). Multivariate analysis revealed that high LAT3 expression and multiple tumors were independent prognostic factors for cancer-specific survival. Furthermore, the rate of p-AKT-positive cases was higher in the LAT3-high group than in the LAT3-low group. Overall, these findings suggested that LAT3 expression was associated with poor prognosis of HCC and high p-AKT expression.
Identifiants
pubmed: 36245821
doi: 10.3892/ol.2022.13538
pii: OL-24-05-13538
pmc: PMC9555019
doi:
Types de publication
Journal Article
Langues
eng
Pagination
418Informations de copyright
Copyright: © Selenge et al.
Déclaration de conflit d'intérêts
MS declares receiving an unrestricted research grant from Bayer Yakuhin, Co. Ltd., Japan. All other authors declare that they have no competing interests.
Références
Cancer Res. 2019 Jul 1;79(13):3220-3234
pubmed: 31101763
Pharmacol Ther. 2022 Feb;230:107964
pubmed: 34390745
Nat Rev Cancer. 2009 Aug;9(8):550-62
pubmed: 19629070
Br J Nutr. 2018 Apr;119(7):727-733
pubmed: 29569540
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Gastroenterol Hepatol. 2014 Dec;29(12):2032-7
pubmed: 24909638
J Natl Cancer Inst. 2013 Oct 2;105(19):1463-73
pubmed: 24052624
Amino Acids. 2010 May;38(5):1361-7
pubmed: 19756942
Curr Med Chem. 2009;16(8):916-30
pubmed: 19275602
Eur J Surg Oncol. 2003 Nov;29(9):735-42
pubmed: 14602492
J Hepatol. 2008 Jan;48(1):83-90
pubmed: 17998146
Cancer Sci. 2021 Sep;112(9):3871-3883
pubmed: 34050700
Front Cell Dev Biol. 2021 Sep 07;9:731790
pubmed: 34557495
Cell Commun Signal. 2019 Jul 25;17(1):83
pubmed: 31345230
Hepatol Res. 2015 Sep;45(9):1014-1022
pubmed: 25297701
Cancer Res. 2011 Dec 15;71(24):7525-36
pubmed: 22007000
ACS Chem Biol. 2014 Jun 20;9(6):1369-76
pubmed: 24762008
Invest New Drugs. 2020 Oct;38(5):1495-1506
pubmed: 32198649
Lung Cancer. 2015 Jul;89(1):13-8
pubmed: 25936472
Anticancer Res. 2011 Nov;31(11):3775-82
pubmed: 22110199
Am J Cancer Res. 2015 Mar 15;5(4):1281-94
pubmed: 26101697
J Huazhong Univ Sci Technolog Med Sci. 2013 Oct;33(5):632-635
pubmed: 24142711